Femasys Inc.

https://femasys.com/

Femasys Inc. is a biomedical company founded in February 2004, headquartered in Suwanee, Georgia, dedicated to transforming women's healthcare. The company's mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies that are accessible in the office, thereby improving patient care and overall health economics. Femasys is led by its founder, President, and CEO, Kathy Lee-Sepsick.

Femasys develops a broad portfolio of in-office therapeutic and diagnostic products primarily focused on reproductive health. Key product candidates and commercialized solutions include FemaSeed, an intratubal insemination solution for infertility; FemBloc, a non-surgical permanent birth control method; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemCerv, an endocervical sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for fallopian tube evaluation; FemChec, a controlled contrast-generating device for fallopian tube diagnosis; and FemSperm, a sperm preparation and analysis product line. These technologies aim to address significant unmet needs in areas such as infertility, contraception, and cancer diagnostics.

In recent news, Femasys launched FemaSeed® Complete for OB/GYNs on April 22, 2026, and expanded its international presence with an Israeli market entry for its fertility portfolio on April 16, 2026. The company also appointed John Canning as Chief Operating Officer on April 1, 2026. Femasys is actively advancing FemBloc toward U.S. approval, having initiated pivotal trial enrollment on March 10, 2026, following its regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025). Additionally, FemBloc achieved MDSAP Certification on February 26, 2026, and FemaSeed received AMA CPT Editorial Panel approval for a new Category III CPT code on February 23, 2026.

Latest updates

Femasys Broadens Fertility Access with In-Office Solution Launch

Event summary

  • Femasys launched FemaSeed Complete, a fertility solution enabling OB/GYNs to perform insemination in-office.
  • The solution combines FemaSeed intratubal insemination (ITI) with FemSperm, streamlining the process.
  • Approximately 10 million US women experience infertility, with less than half seeking care.
  • Femasys estimates fewer than 2,000 infertility specialists serve the US market, limiting access.

The big picture

Femasys is capitalizing on a fragmented fertility care market where access is limited by specialist availability. By shifting first-line treatment to OB/GYN offices, the company aims to expand its addressable market and reduce patient wait times. This strategy represents a potential disruption to the traditional fertility clinic model, but its success depends on physician buy-in and patient acceptance of a less specialized approach.

What we're watching

Market Adoption
The success of FemaSeed Complete hinges on OB/GYN adoption rates, which will dictate the speed of market penetration and revenue generation.
Clinical Data
Continued positive clinical data demonstrating efficacy and safety will be crucial for maintaining physician confidence and attracting patients.
Regulatory Risk
The ongoing FINALE trial for FemBloc's US FDA approval presents a significant regulatory risk that could impact overall company valuation.

Femasys Expands Fertility Portfolio with Israeli Market Entry

Event summary

  • Femasys has partnered with AMI Technologies to commercialize its fertility portfolio, including FemaSeed and FemVue, in Israel.
  • The partnership leverages AMI Technologies’ existing infrastructure and market expertise in Israel’s fertility care sector.
  • FemaSeed is positioned as a first-line infertility treatment in Israel, offering a potentially more effective alternative to IUI.
  • AMI Technologies is a provider of advanced medical technologies in Israel, representing European and US medical device manufacturers.

The big picture

Femasys’s entry into the Israeli market represents a strategic move to expand its international footprint in the rapidly growing fertility care sector. Israel’s advanced reproductive technology infrastructure and focus on innovation make it an attractive market for Femasys’s differentiated fertility solutions. This partnership highlights a broader trend of biomedical companies leveraging local expertise to navigate complex regulatory environments and accelerate market access in international territories.

What we're watching

Market Adoption
The speed of FemaSeed adoption within Israeli fertility centers will be a key indicator of the partnership’s success and the product’s viability in a new market.
Regulatory Landscape
Continued regulatory approvals and reimbursement pathways in international markets will be crucial for Femasys’s broader global expansion plans.
Competitive Dynamics
How AMI Technologies’ existing relationships with healthcare providers will influence the competitive landscape for FemaSeed against established IUI and IVF treatments warrants monitoring.

Femasys Appoints Seasoned MedTech Exec to Bolster Operations

Event summary

  • Femasys appointed John Canning as Chief Operating Officer, effective April 1, 2026.
  • Canning brings over 25 years of experience in medical device operations, most recently as COO/CTO at Terumo Aortic.
  • He previously served as COO at Bolton Medical, which Terumo Aortic acquired.
  • Femasys granted Canning 150,000 inducement stock options vesting over four years.
  • The appointment aims to strengthen operational capabilities and support commercial growth of Femasys’ fertility and birth control portfolio.

The big picture

Femasys's move to bring in Canning signals a shift towards prioritizing operational scalability as the company expands its commercial footprint. The appointment addresses a common challenge for rapidly growing biomedical innovators – transitioning from a research-driven phase to a commercially viable enterprise. Canning’s experience in acquisitions and pipeline advancement suggests Femasys may be positioning itself for further strategic consolidation within the women’s health market.

What we're watching

Execution Risk
Canning’s success hinges on integrating his operational expertise with Femasys’ existing culture and processes, which could present challenges given the company’s rapid growth phase.
Regulatory Headwinds
The FINALE trial for FemBloc’s FDA approval remains critical; delays or unfavorable results could significantly impact commercialization timelines and investor sentiment.
Commercial Traction
The effectiveness of strategic partnerships in Europe for FemBloc commercialization will determine the speed and scale of international expansion, and whether it can offset US regulatory risk.

Femasys Advances Birth Control Portfolio, Burns Cash at Accelerated Rate

Event summary

  • Femasys reported $2.29 million in sales for 2025, a 40.8% increase primarily driven by FemBloc sales.
  • The company initiated a pivotal clinical trial (FINALE) for FemBloc, a key step towards U.S. FDA approval.
  • Research and development expenses decreased to $7.58 million, largely due to product commercialization and reduced compensation costs.
  • Femasys secured $12 million in financing, projecting sufficient cash runway into Q3 2026.
  • The company incurred a net loss of $18.63 million for 2025, slightly improved from $18.82 million the prior year.

The big picture

Femasys is attempting to disrupt the fertility and birth control markets with novel, in-office procedures, a strategy that requires significant upfront investment and regulatory navigation. While the company has made progress in securing approvals and partnerships, its persistent net losses and dependence on external funding highlight the challenges of scaling a biomedical innovation business. The FINALE trial represents a pivotal moment, as successful approval of FemBloc could unlock significant revenue potential, but failure would likely necessitate further capital raises or a strategic pivot.

What we're watching

Clinical Execution
The FINALE trial's enrollment and subsequent data readouts will be critical in determining the timeline and likelihood of FemBloc's U.S. approval, directly impacting the company's valuation.
Cash Burn
While the $12 million financing extends the cash runway, the company's continued reliance on external funding and significant net losses raise questions about long-term financial sustainability.
Reimbursement
The new CPT code for FemaSeed is a positive step, but the actual adoption and reimbursement rates by insurers will dictate the product's commercial success and revenue generation.

Femasys Adds Anesthesiologist with Biotech Investment Experience to Board

Event summary

  • Femasys appointed Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors, effective immediately.
  • Dr. Eichenbaum brings 20+ years of experience evaluating biotech and medical device companies and advising investment firms.
  • Femasys acknowledged the departure of Joshua Silverman from the Board.
  • Dr. Eichenbaum holds degrees from Stanford, Mount Sinai, University of Pennsylvania, and Wharton.

The big picture

Femasys’s board refresh signals a potential shift towards a more data-driven and financially disciplined approach, particularly as the company seeks FDA approval for FemBloc and expands its international presence. The departure of Silverman, who provided capital markets expertise, suggests a possible reassessment of the company’s financing strategy. The addition of Dr. Eichenbaum, with his combined clinical, technical, and financial background, aims to bolster the company’s strategic decision-making process.

What we're watching

Governance Dynamics
The addition of an anesthesiologist with investment experience suggests a desire for more rigorous financial oversight and clinical validation of Femasys’s product pipeline.
Regulatory Headwinds
The FINALE trial for FemBloc’s FDA approval remains critical; Dr. Eichenbaum’s expertise may influence trial design and data interpretation.
Execution Risk
The company’s reliance on strategic partnerships for FemBloc commercialization in Europe will determine the product’s overall success and revenue generation.

Femasys Advances U.S. Birth Control Push with Pivotal Trial Start

Event summary

  • Femasys initiated enrollment in the FINALE pivotal clinical trial for FemBloc, its non-surgical permanent birth control product.
  • The trial follows FDA Investigational Device Exemption (IDE) approval based on positive prior clinical data.
  • FemBloc is already approved and commercialized in Europe, the UK, and New Zealand.
  • The FINALE trial aims to support a future U.S. regulatory submission, with completion expected later in 2026.
  • The trial will enroll 401 women, with an interim analysis planned after 300 complete one year of use.

The big picture

Femasys is attempting to disrupt a multi-billion dollar market dominated by surgical sterilization procedures. The FINALE trial represents a high-stakes bet on the viability of a non-surgical alternative, and its success could significantly alter the landscape of women's reproductive healthcare. The company's broader portfolio of fertility products suggests a strategic focus on reproductive health solutions, but FemBloc’s U.S. approval is key to unlocking substantial revenue potential.

What we're watching

Clinical Outcomes
The FINALE trial's primary endpoint – pregnancy rate – will be critical; a failure to demonstrate efficacy could significantly delay or derail U.S. approval.
Market Adoption
The success of FemBloc in the U.S. will depend on physician adoption and patient willingness to embrace a novel, non-surgical procedure, potentially requiring significant marketing and education efforts.
Competitive Landscape
While FemBloc is currently unique, the emergence of competing non-surgical birth control options could erode its market share and pricing power, especially if the FDA approval process is protracted.

Femasys Secures MDSAP Certification, Streamlining Global Expansion for FemBloc

Event summary

  • Femasys has achieved Medical Device Single Audit Program (MDSAP) certification for its FemBloc permanent birth control system.
  • The certification facilitates regulatory approvals in the U.S., Canada, Japan, Australia, and Brazil.
  • FemBloc is the latest Femasys product to receive MDSAP certification, aligning with the company's existing compliance framework.
  • The FINALE pivotal trial (NCT05977751) for U.S. FDA approval is currently ongoing.

The big picture

Femasys's MDSAP certification represents a crucial step in its strategy to disrupt the surgical sterilization market, a segment estimated to be worth billions globally. The certification streamlines regulatory pathways and enhances credibility, but the company's success hinges on the FINALE trial results and the effective execution of its commercialization partnerships. The move underscores the growing trend of companies seeking non-surgical alternatives to established medical procedures to improve patient outcomes and reduce healthcare costs.

What we're watching

Regulatory Headwinds
The speed of FDA approval for FemBloc following the FINALE trial will be a key indicator of the product's commercial viability in the U.S. market, and any delays could impact investor sentiment.
Partnership Dynamics
The success of Femasys's strategic partnerships in Europe will determine the pace of commercialization and revenue generation in those markets, and the terms of those agreements remain opaque.
Execution Risk
Scaling manufacturing to meet anticipated global demand, while maintaining the quality standards reflected in the MDSAP certification, presents a significant operational challenge for Femasys.

Femasys Secures CPT Code for Infertility Treatment, Paving Way for Reimbursement

Event summary

  • Femasys received approval from the AMA CPT Editorial Panel for a new Category III CPT code covering FemaSeed Intratubal Insemination (ITI).
  • The new code is expected to be publicly issued by the AMA with an effective date of January 1, 2027.
  • The code aims to advance reimbursement strategy for FemaSeed, supporting broader clinical adoption and patient access.
  • FemaSeed is a first-step infertility treatment designed to bridge the gap between IUI and IVF.
  • Clinical trials showed FemaSeed achieved more than double the pregnancy rates of IUI.

The big picture

The approval of a new CPT code is a crucial, albeit incremental, step in the reimbursement process for novel medical procedures. Femasys's move signals a strategic shift towards broader adoption of its FemaSeed technology, which aims to disrupt the existing infertility treatment landscape dominated by IUI and IVF. The company's success hinges on its ability to navigate the complexities of reimbursement and provider adoption within a market estimated to affect millions of women annually.

What we're watching

Reimbursement Adoption
The speed at which insurance providers adopt the new CPT code will directly impact Femasys's ability to scale FemaSeed's commercialization and patient access.
Clinical Uptake
How quickly gynecologists integrate FemaSeed into their treatment protocols, and the impact of this adoption on overall pregnancy rates, will be key indicators of success.
Competitive Landscape
The emergence of competing intratubal insemination technologies or alternative infertility treatments could challenge Femasys's market position and pricing power.

Femasys Expands European Reach with Swiss Distribution Deal

Event summary

  • Femasys has partnered with Swiss firm OR Consulting to distribute its fertility and birth control products, including FemBloc, FemaSeed, and FemVue, in Switzerland.
  • This partnership follows Femasys’ recent market entries in Spain and France, forming part of a broader European expansion strategy.
  • OR Consulting brings experience in medical technology distribution and gynecologic solutions, particularly in the Swiss market.
  • FemBloc received European regulatory approval in June 2025, marking the first non-surgical, in-office alternative to surgical sterilization.

The big picture

Femasys’ European expansion strategy, relying on regional partnerships, reflects a common approach for smaller biomedical firms seeking to navigate complex regulatory landscapes and fragmented markets. The Swiss market, known for its sophistication and high healthcare standards, represents a valuable but challenging entry point. This partnership underscores the growing demand for innovative, non-invasive women’s health solutions, particularly in fertility and contraception.

What we're watching

Market Adoption
The success of the partnership hinges on OR Consulting’s ability to effectively integrate Femasys’ products into the Swiss healthcare system and drive physician adoption.
Regulatory Risk
While FemBloc has European approval, the ongoing FINALE trial for US FDA approval remains a key risk factor, potentially impacting broader commercialization plans.
Competitive Landscape
The emergence of non-surgical alternatives to sterilization could intensify competition within the women’s health market, requiring Femasys to differentiate its offerings.

Femasys Gains Nasdaq Extension to Avoid Delisting

Event summary

  • Femasys received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement.
  • The extension, granted January 13, 2026, provides until July 13, 2026, to achieve compliance.
  • Nasdaq’s decision was contingent on Femasys meeting other listing requirements and indicating a potential reverse stock split.
  • Compliance will be triggered if the share price closes above $1.00 for ten consecutive business days.

The big picture

Femasys's Nasdaq compliance issue highlights the challenges faced by smaller, growth-stage biomedical companies reliant on capital markets. The extension provides a temporary reprieve, but the underlying problem – a depressed share price – reflects concerns about the company's commercial execution and the long timelines inherent in bringing innovative medical products to market. The potential for a reverse stock split introduces further uncertainty for investors.

What we're watching

Reverse Split
The company's stated intention to consider a reverse stock split signals a potential willingness to take drastic measures to maintain Nasdaq listing, which could negatively impact existing shareholders.
Share Price
The ability of Femasys to sustain a share price above $1.00 will depend on market sentiment and the successful commercialization of its fertility and birth control products, particularly FemBloc in international markets.
FDA Approval
The ongoing FINALE trial for FemBloc’s U.S. FDA approval is critical; a positive outcome would likely boost investor confidence and the share price, but delays or setbacks could further exacerbate the compliance issue.

Femasys Partners with Refuah Health to Expand Fertility Treatment Access

Event summary

  • Femasys has partnered with Refuah Health Center to offer FemaSeed as a first-line infertility treatment option.
  • The partnership aims to expand Femasys’ commercial footprint in community-based fertility care.
  • FemaSeed is a directional intratubal insemination solution that reportedly achieves over double the pregnancy rates of traditional IUI.
  • Refuah Health Center is a Federally Qualified Community Health Center serving the Hudson Valley region of New York.

The big picture

Femasys’s strategy of targeting community-based care centers represents a deliberate effort to broaden access to its fertility treatments beyond specialized clinics. This partnership with Refuah Health Center aligns with the broader trend of healthcare providers seeking more cost-effective and patient-centered solutions for infertility, and could accelerate FemaSeed’s adoption within a significant segment of the market. The company’s focus on both fertility and contraception (FemBloc) suggests a long-term play in women’s health, but execution remains critical.

What we're watching

Adoption Rate
The success of this partnership hinges on Refuah Health Center’s ability to integrate FemaSeed into its existing patient workflows and drive adoption among its patient base, which will be a key indicator of broader market acceptance.
Clinical Validation
Continued clinical data demonstrating FemaSeed's efficacy and safety compared to IUI will be crucial for maintaining physician and patient confidence and expanding reimbursement coverage.
Competitive Landscape
The emergence of FemaSeed as a first-line treatment could shift the competitive dynamics within the fertility market, potentially impacting the utilization rates of other established procedures like intrauterine insemination (IUI) and in-vitro fertilization (IVF).

Femasys Gains FDA Clearance for Integrated Fallopian Tube Diagnostic

Event summary

  • Femasys received 510(k) clearance from the FDA for the FemVue Controlled diagnostic device on December 18, 2025.
  • The device integrates the company’s existing FemVue and FemChec technologies into a single platform.
  • FemVue Controlled is designed to evaluate fallopian tube status using controlled contrast delivery during ultrasound imaging.
  • The device is intended to streamline workflows and enable multiple clinical uses, including confirmation of tubal patency prior to FemaSeed use.

The big picture

Femasys's focus on non-surgical contraception and fertility treatments addresses a growing market demand for less invasive and more accessible options. The integration of FemVue and FemChec into a single device represents a strategic move to improve operational efficiency and expand the utility of its diagnostic portfolio. This clearance strengthens Femasys’s position in a competitive landscape, but the company’s long-term success hinges on successful commercialization and regulatory approvals for its broader product pipeline, including FemBloc.

What we're watching

Commercialization
The speed of adoption by clinicians will be key to realizing the device's potential to streamline workflows and increase Femasys’s market penetration within the fertility and contraception space.
Regulatory Risk
The ongoing FINALE trial for FemBloc’s U.S. FDA approval presents a significant regulatory hurdle, and any setbacks could impact investor sentiment surrounding the broader Femasys portfolio.
Integration
How effectively Femasys integrates the FemVue Controlled device into its existing product offerings, particularly alongside FemaSeed, will determine its overall impact on revenue and market share.
CID: 496